Equity Profile

NBIX

Neurocrine Biosciences, Inc.

Health CareBiotechnology$15.3B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine disorders....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and this quarter's consensus reflects strong growth expectations.

$1.96

Revenue

Revenue figures provide insights into the company's sales performance and market demand for its products.

$890M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine disorders. With a market cap of $15 billion, its innovative therapies address significant unmet medical needs, making it a key player in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1-2026, Neurocrine reported an EPS of $1.94, significantly beating expectations by 51.21%. The stock reacted positively, gaining 0.74% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings in neurological disorders.
Commitment to maintaining strong sales growth in existing therapies.
Plans to invest in research and development for new treatments.

Expectations

Wall Street Expectations

Analysts are optimistic about Neurocrine's upcoming earnings, expecting continued strong performance based on past results. The company has consistently beaten EPS estimates in recent quarters.

Bull Case

If Neurocrine exceeds the EPS and revenue expectations, it could signal robust demand for its products and further validate its growth strategy.

Bear Case

Conversely, any signs of declining sales or unmet expectations could raise concerns about the sustainability of its growth and lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.96

Earnings per share is a critical measure of profitability, and this quarter's consensus reflects strong growth expectations.

Revenue

$890M

Revenue figures provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.96, confirming the company's strong growth trajectory?

A beat on EPS would reinforce investor confidence in Neurocrine's ability to deliver consistent profitability.

What revenue figures will be reported, and how do they compare to the $890M consensus?

Revenue performance is critical for assessing market demand and the effectiveness of the company's sales strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Neurocrine's ability to maintain its growth momentum, especially given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend of stronger-than-expected results.

Options pricing indicates a higher expected move than historical averages, suggesting potential for a significant reaction.

The lack of recent peer reports may indicate that Neurocrine's unique position in the market is not fully appreciated.

Key Risk

If EPS comes in below $1.96, it could challenge the current bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these metrics to gauge the company's ongoing performance and future prospects.

Bull Confirmed If

Exceeding $1.96 in EPS would confirm strong operational performance and growth potential.

Bear Confirmed If

Falling below $890M in revenue could raise concerns about market demand and growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.78%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a move of about 3.78%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by about 2.03%, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, the average historical reaction indicates a potential decline, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into sales performance for existing therapies.
3Management's outlook on market conditions and competitive landscape.
4Discussion of R&D investments and future growth strategies.
5Any changes to guidance or expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine disorders....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and this quarter's consensus reflects strong growth expectations.

$1.96

Revenue

Revenue figures provide insights into the company's sales performance and market demand for its products.

$890M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1-2026, Neurocrine reported an EPS of $1.94, significantly beating expectations by 51.21%. The stock reacted positively, gaining 0.74% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings in neurological disorders.
Commitment to maintaining strong sales growth in existing therapies.
Plans to invest in research and development for new treatments.

Expectations

Wall Street Expectations

Analysts are optimistic about Neurocrine's upcoming earnings, expecting continued strong performance based on past results. The company has consistently beaten EPS estimates in recent quarters.

Bull Case

If Neurocrine exceeds the EPS and revenue expectations, it could signal robust demand for its products and further validate its growth strategy.

Bear Case

Conversely, any signs of declining sales or unmet expectations could raise concerns about the sustainability of its growth and lead to a negative market reaction.

Key Metrics to Watch

EPS

$1.96

Earnings per share is a critical measure of profitability, and this quarter's consensus reflects strong growth expectations.

Revenue

$890M

Revenue figures provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.96, confirming the company's strong growth trajectory?

A beat on EPS would reinforce investor confidence in Neurocrine's ability to deliver consistent profitability.

What revenue figures will be reported, and how do they compare to the $890M consensus?

Revenue performance is critical for assessing market demand and the effectiveness of the company's sales strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Neurocrine's ability to maintain its growth momentum, especially given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend of stronger-than-expected results.

Options pricing indicates a higher expected move than historical averages, suggesting potential for a significant reaction.

The lack of recent peer reports may indicate that Neurocrine's unique position in the market is not fully appreciated.

Key Risk

If EPS comes in below $1.96, it could challenge the current bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these metrics to gauge the company's ongoing performance and future prospects.

Bull Confirmed If

Exceeding $1.96 in EPS would confirm strong operational performance and growth potential.

Bear Confirmed If

Falling below $890M in revenue could raise concerns about market demand and growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.78%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a move of about 3.78%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by about 2.03%, confirming a strong growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, the average historical reaction indicates a potential decline, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into sales performance for existing therapies.
3Management's outlook on market conditions and competitive landscape.
4Discussion of R&D investments and future growth strategies.
5Any changes to guidance or expectations for the upcoming quarters.